Revance Appoints David A. Hollander, M.D., M.B.A. as Chief Medical Officer
Copyright 2022, Business Wire.
news
2022-10-17 12:00:00

October 17, 2022 08:00 AM Eastern Daylight Time NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the appointment of David A. Hollander, M.D., M.B.A., as Chief Medical Officer to lead clinical development, data science, medical affairs, scientific innovation, pharmacovigilance and regulatory affairs.



'David joins Revance at an exciting time, as we turn our sights towards aesthetics commercial launch, international regulatory strategy, and the advancement of our therapeutics opportunity and biosimilar to BotoxÂ® program,' said Dustin S.
